Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.
Kanate AS, Craig M, Cumpston A, Saad A, Hobbs G, Leadmon S, Bunner P, Watkins K, Bulian D, Gibson L, Abraham J, Remick SC, Hamadani M. Kanate AS, et al. Among authors: gibson l. Hematol Oncol Stem Cell Ther. 2011;4(4):149-56. doi: 10.5144/1658-3876.2011.149. Hematol Oncol Stem Cell Ther. 2011. PMID: 22198185 Free article.
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.
Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine SM. Hamadani M, et al. Among authors: gibson l. Hematol Oncol. 2011 Dec;29(4):202-10. doi: 10.1002/hon.985. Epub 2011 Feb 28. Hematol Oncol. 2011. PMID: 21360728 Free PMC article.
Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.
Awan FT, Osman S, Kochuparambil ST, Gibson L, Remick SC, Abraham J, Craig M, Jillella A, Hamadani M. Awan FT, et al. Among authors: gibson l. Bone Marrow Transplant. 2012 Jan;47(1):146-8. doi: 10.1038/bmt.2011.18. Epub 2011 Feb 28. Bone Marrow Transplant. 2012. PMID: 21358681 Clinical Trial. No abstract available.
Mis-expression of GATA6 re-programs cell fate during early hematopoiesis.
Audiger C, Laâbi Y, Nie J, Gibson L, Wilson-Annan J, Brook-Carter P, Kueh A, Harris AW, Naik S, Nutt SL, Strasser A, Adams JM, Bouillet P, Chopin M. Audiger C, et al. Among authors: gibson l. Cell Rep. 2024 Apr 26;43(5):114159. doi: 10.1016/j.celrep.2024.114159. Online ahead of print. Cell Rep. 2024. PMID: 38676923 Free article.
Anti-tumor activity of a novel LAIR1 antagonist in combination with anti-PD-1 to treat collagen-rich solid tumors.
Rodriguez BL, Huang J, Gibson L, Fradette JJ, Chen HH, Koyano K, Cortez C, Li B, Ho C, Ashique AM, Lin VY, Crawley S, Roda JM, Chen P, Fan B, Kim J, Sissons J, Sitrin J, Kaplan DD, Gibbons DL, Rivera LB. Rodriguez BL, et al. Among authors: gibson l. Mol Cancer Ther. 2024 Apr 22. doi: 10.1158/1535-7163.MCT-23-0866. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38648067
1,293 results